Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators

Patent metadata

Field	Value
Publication number	US-9957271-B2
Application number	US-201214353096-A
Country	US
Kind code	B2
Filing date	Oct 19, 2012
Priority date	Oct 20, 2011
Publication date	May 1, 2018
Grant date	May 1, 2018

Abstract

Provided herein are novel substituted bicyclic aza-heterocycle sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

First claim

We claim:

1. A compound which is

Compound No
Structure

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

Assignees

• Glaxosmithkline Llc
• Glaxosmithkline Llc

Inventors

• Casaubon Rebecca L
• Narayan Radha
• Oalmann Christopher
• Vu Chi B

Classifications

• A61P5/50

  for increasing or potentiating the activity of insulin · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• C07D519/00

  Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 · CPC title

• A61K31/5377

  not condensed and containing further heterocyclic rings, e.g. timolol · CPC title